Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, doing business as Adaptive, is a Seattle-based for-profit clinical diagnostics and immunosequencing services provider that operates exclusively as a federal prime contractor, delivering FDA-cleared minimal residual disease testing and immune-repertoire sequencing to civilian research and defense medical agencies through purchase orders, blanket purchase agreements, and a definitive contract with no set-aside designations across its federal footprint.

Adaptive's core capability is immunosequencing and ClonoSEQ-based minimal residual disease detection — FDA-cleared in vitro diagnostic tests that identify and monitor clonal populations in blood cancers including multiple myeloma and chronic lymphocytic leukemia. The vendor delivers these services through laboratory testing and deep sequencing of T-cell and B-cell receptor repertoires to support clinical diagnostics, treatment monitoring, and research missions. Representative federal work includes a $577,920 definitive contract awarded by the Defense Health Agency on March 14, 2025, for ClonoSEQ testing services at JBSA Fort Sam Houston running through March 2030; a $224,250 purchase order from the Defense Health Agency (February 28, 2025) for FDA-cleared ClonoSEQ in vitro diagnostic testing services at Bethesda, Maryland; an $828,750 single-award blanket purchase agreement with the Department of Veterans Affairs Veterans Integrated Service Network 1 (July 15, 2022, through June 30, 2027) providing ClonoSEQ testing to VA medical facilities in New England, under which six BPA calls totaling $167 thousand have been issued to date; and a $308,400 COVID-19-funded immunosequencing contract from the National Institute of Allergy and Infectious Diseases (November 10, 2022) for immunosequencing services supporting pandemic research.

Adaptive's customer concentration is heavily weighted toward the National Institutes of Health. The top five funding agencies account for 84% of recent awards and combined potential value. The National Institute of Allergy and Infectious Diseases leads by both count (44 awards, $1.4 million combined potential value) and dollar share, followed by the National Cancer Institute (34 awards, $1 million), the Defense Health Agency (4 awards, $1.3 million), and the Department of Veterans Affairs Veterans Integrated Service Network 1 (7 awards, $996 thousand). The National Heart Lung and Blood Institute (12 awards, $182 thousand) and the NIH Clinical Center (3 awards, $298 thousand) round out the active set. The two rankings diverge slightly — the Defense Health Agency ranks second by dollar value despite only four awards, reflecting the higher contract values on DHA definitive and standing purchase orders compared to NIH's volume-driven portfolio of smaller research-support purchases.

Adaptive holds a single material parent vehicle: the VA Veterans Integrated Service Network 1 BPA (36C24122A0124) with an $828,750 ceiling extending through June 30, 2027. The BPA has generated six task orders since award, beginning with initial calls in July 2022 and continuing through July 2026, providing recurring ClonoSEQ testing to VA medical centers in Boston, West Haven, West Roxbury, and Seattle. The vendor operates entirely through full-and-open competition; none of its 120 recent awards employ set-aside designations.

Activity has been uneven over the past five years, declining from eight awards in 2022 to three in 2026 year-to-date, though the overall award count of 120 reflects sustained engagement across fourteen federal customer agencies since 2010. However, combined potential value ($6 million) is materially smaller than combined dollars obligated ($8.1 million, or 136% of potential value), a signal that older awards have been invoiced above their original ceiling values as test volumes or pricing adjustments have escalated. Four awards with ultimate completion dates in the next twenty-four months carry combined potential value of $332 thousand, representing modest recompete exposure; the largest near-term completion is the VISN 1 BPA call ordered July 15, 2026 ($35,100), due July 14, 2027.

Adaptive operates as a pure prime contractor — all 120 awards in the source are prime positions, with zero sub-award activity. The vendor's federal service footprint reflects specialized laboratory testing and immunosequencing delivery performed in Seattle and at customer sites including VA medical centers across New England, Defense Health Agency locations in Texas and Maryland, and NIH facilities in Bethesda. The SCI dataset captures minimal activity: one record from FY2022 showing 0.4 FTEs in a named subcontractor position, indicating that Adaptive's true federal revenue is substantially underrepresented in Service Contract Inventory and concentrated in goods and services purchases below or outside SCI thresholds.